Eli Lilly (LLY) stock is in focus as the company launches Employer Connect to improve employee access to its obesity therapy ...

A service tailored to people with workplace-based insurance coverage represents a new way for Lilly to bypass insurers and expand use of its popular obesity shot.

Eli Lilly hopes the device can be more convenient for Zepbound users and lead to more people taking the drug.

Eli Lilly and Co. (LLY) on Monday announced a new version of its blockbuster weight-loss drug Zepbound, available in a ...

Lilly Employer Connect aims to make obesity treatments more predictable for employers while lowering costs for workers ...

Eli Lilly announced on "Good Morning America" Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new ...

March 5 (Reuters) - Eli Lilly said on Thursday it has rolled out a platform to help employers connect with organizations ...

Forget the drug discovery hype. Here’s how the world’s largest pharma company is seeing a payoff from AI right now.

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Novo Nordisk is losing to Eli Lilly in the fiercely competitive weight loss market. But one of the company's mid-stage assets could help it remain a key player.

Novo Nordisk's Kagrama stumbles versus Zepbound, forcing investors to reassess obesity‑drug expectations.

Eli Lilly (NYSE: LLY) wasn't the first to market with a GLP-1 drug. However, its Mounjaro (for diabetes) and Zepbound (for ...